These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25119130)

  • 21. Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.
    Palavutitotai N; Jitmuang A; Tongsai S; Kiratisin P; Angkasekwinai N
    PLoS One; 2018; 13(2):e0193431. PubMed ID: 29470531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infections due to multidrug-resistant organisms following heart transplantation: Epidemiology, microbiology, and outcomes.
    Bhatt PJ; Ali M; Rana M; Patel G; Sullivan T; Murphy J; Pinney S; Anyanwu A; Huprikar S; Taimur S
    Transpl Infect Dis; 2020 Feb; 22(1):e13215. PubMed ID: 31765045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
    Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing mortality in solid organ transplant recipients with bloodstream infection.
    Oriol I; Sabé N; Melilli E; Lladó L; González-Costello J; Soldevila L; Carratalà J
    Clin Microbiol Infect; 2015 Dec; 21(12):1104.e9-14. PubMed ID: 26253289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.
    Samonis G; Vardakas KZ; Kofteridis DP; Dimopoulou D; Andrianaki AM; Chatzinikolaou I; Katsanevaki E; Maraki S; Falagas ME
    Infection; 2014 Aug; 42(4):721-8. PubMed ID: 24912861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Mortality in Abdominal Organ Transplant Recipients with Pseudomonas aeruginosa Infections.
    Su H; Ye Q; Wan Q; Zhou J
    Ann Transplant; 2016 Feb; 21():86-93. PubMed ID: 26856368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteremia and septic shock after solid-organ transplantation.
    Candel FJ; Grima E; Matesanz M; Cervera C; Soto G; Almela M; Martínez JA; Navasa M; Cofán F; Ricart MJ; Pérez-Villa F; Moreno A
    Transplant Proc; 2005 Nov; 37(9):4097-9. PubMed ID: 16386636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Distribution and Resistance of Pathogens Among Solid Organ Transplant Recipients with Pseudomonas aeruginosa Infections.
    Luo A; Zhong Z; Wan Q; Ye Q
    Med Sci Monit; 2016 Apr; 22():1124-30. PubMed ID: 27045418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
    Sun HY; Shields RK; Cacciarelli TV; Muder RR; Singh N
    Transpl Infect Dis; 2010 Dec; 12(6):555-60. PubMed ID: 20626709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients.
    Gómez-Zorrilla S; Camoez M; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5863-70. PubMed ID: 25049255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
    Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
    Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes.
    Wagener MM; Yu VL
    Am J Infect Control; 1992 Oct; 20(5):239-47. PubMed ID: 1443756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
    Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
    Oliveira AL; de Souza M; Carvalho-Dias VM; Ruiz MA; Silla L; Tanaka PY; Simões BP; Trabasso P; Seber A; Lotfi CJ; Zanichelli MA; Araujo VR; Godoy C; Maiolino A; Urakawa P; Cunha CA; de Souza CA; Pasquini R; Nucci M
    Bone Marrow Transplant; 2007 Jun; 39(12):775-81. PubMed ID: 17438585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital.
    Kiddee A; Henghiranyawong K; Yimsabai J; Tiloklurs M; Niumsup PR
    Int J Antimicrob Agents; 2013 Oct; 42(4):301-6. PubMed ID: 23845503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
    Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
    Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.